György Miklós Keserű

György obtained his Ph.D. at Budapest, Hungary and joined Sanofi heading a chemistry research lab. He moved to Gedeon Richter in 1999 as the Head of Computer-aided Drug Discovery. Since 2007 he was appointed as the Head of Discovery Chemistry at Gedeon Richter. He contributed to the discovery of the antipsychotic Vraylar® (cariprazine) that has been approved and marketed from 2016 in US and EU. He served as a director general of the Research Centre for Natural Sciences (RCNS) at the Hungarian Academy of Sciences. From 2015 he is heading the Medicinal Chemistry Research Group at RCNS. More recently György has been appointed as the Head of the National Drug Discovery and Development Laboratory. He has published over 340 papers and more than 10 books and book chapters. György was awarded by the prestigious Overton and Meyer Award of the European Federation of Medicinal Chemistry. He has been elected as Fellow of the Royal Society of Chemistry, as member of the Hungarian Academy of Sciences and Academia Europaea.